165 related articles for article (PubMed ID: 37352862)
1. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets.
Griger J; Widholz SA; Jesinghaus M; de Andrade Krätzig N; Lange S; Engleitner T; Montero JJ; Zhigalova E; Öllinger R; Suresh V; Winkler W; Lier S; Baranov O; Trozzo R; Ben Khaled N; Chakraborty S; Yu J; Konukiewitz B; Steiger K; Pfarr N; Rajput A; Sailer D; Keller G; Schirmacher P; Röcken C; Fagerstedt KW; Mayerle J; Schmidt-Supprian M; Schneider G; Weichert W; Calado DP; Sommermann T; Klöppel G; Rajewsky K; Saur D; Rad R
Cancer Cell; 2023 Jul; 41(7):1327-1344.e10. PubMed ID: 37352862
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas.
Koh J; Nam SK; Kwak Y; Kim G; Kim KK; Lee BC; Ahn SH; Park DJ; Kim HH; Park KU; Kim WH; Lee HS
J Pathol; 2021 Jan; 253(1):94-105. PubMed ID: 32985687
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal and molecular pathway alterations in the neuroendocrine carcinoma and adenocarcinoma components of gastric mixed neuroendocrine-nonneuroendocrine neoplasm.
Sun L; Zhang J; Wang C; Zhao S; Shao B; Guo Y; Liu Y; Sun Y
Mod Pathol; 2020 Dec; 33(12):2602-2613. PubMed ID: 32461621
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
[TBL] [Abstract][Full Text] [Related]
5. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
7. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
[TBL] [Abstract][Full Text] [Related]
8. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
Dayton TL; Alcala N; Moonen L; den Hartigh L; Geurts V; Mangiante L; Lap L; Dost AFM; Beumer J; Levy S; van Leeuwaarde RS; Hackeng WM; Samsom K; Voegele C; Sexton-Oates A; Begthel H; Korving J; Hillen L; Brosens LAA; Lantuejoul S; Jaksani S; Kok NFM; Hartemink KJ; Klomp HM; Borel Rinkes IHM; Dingemans AM; Valk GD; Vriens MR; Buikhuisen W; van den Berg J; Tesselaar M; Derks J; Speel EJ; Foll M; Fernández-Cuesta L; Clevers H
Cancer Cell; 2023 Dec; 41(12):2083-2099.e9. PubMed ID: 38086335
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of gastric neuroendocrine carcinomas.
Ikegame K; Hatakeyama K; Terashima M; Sugino T; Aizawa D; Furukawa K; Fujiya K; Tanizawa Y; Bando E; Yamaguchi K
Eur J Surg Oncol; 2023 Sep; 49(9):106987. PubMed ID: 37463826
[TBL] [Abstract][Full Text] [Related]
10. Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins.
Qiu MZ; Chen Q; Zheng DY; Zhao Q; Wu QN; Zhou ZW; Yang LQ; Luo QY; Sun YT; Lai MY; Yuan SS; Wang FH; Luo HY; Wang F; Li YH; Zhang HZ; Xu RH
Cell Rep; 2023 Jun; 42(6):112576. PubMed ID: 37285266
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Dijkstra KK; van den Berg JG; Weeber F; van de Haar J; Velds A; Kaing S; Peters DDGC; Eskens FALM; de Groot DA; Tesselaar MET; Voest EE
Front Endocrinol (Lausanne); 2021; 12():627819. PubMed ID: 33776923
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants.
Matsui K; Jin XM; Kitagawa M; Miwa A
Arch Pathol Lab Med; 1998 Nov; 122(11):1010-7. PubMed ID: 9822131
[TBL] [Abstract][Full Text] [Related]
13. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms.
Sun L; Wang C; Zhang J; Shao B; Zhao S; Guo Y; Li X; Sun Y
Mod Pathol; 2022 Jun; 35(6):808-815. PubMed ID: 34839352
[TBL] [Abstract][Full Text] [Related]
15. RUNDC3A/SNAP25/Akt signaling mediates tumor progression and chemoresistance in gastric neuroendocrine carcinoma.
Lin Z; Kwok HF
Cell Death Dis; 2022 Oct; 13(10):840. PubMed ID: 36182960
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma.
Lim SM; Kim H; Kang B; Kim HS; Rha SY; Noh SH; Hyung WJ; Cheong JH; Kim HI; Chung HC; Yun M; Cho A; Jung M
Ann Nucl Med; 2016 May; 30(4):279-86. PubMed ID: 26837515
[TBL] [Abstract][Full Text] [Related]
17. NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms.
Gerstberger S; Ganesh K
Cancer Cell; 2023 Dec; 41(12):2014-2016. PubMed ID: 38086333
[TBL] [Abstract][Full Text] [Related]
18. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.
Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS
J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436
[TBL] [Abstract][Full Text] [Related]
19. Mucin phenotype expression of gastric neuroendocrine neoplasms: analysis of histopathology and carcinogenesis.
Domori K; Nishikura K; Ajioka Y; Aoyagi Y
Gastric Cancer; 2014 Apr; 17(2):263-72. PubMed ID: 23828549
[TBL] [Abstract][Full Text] [Related]
20. Treatment landscape of advanced high-grade neuroendocrine neoplasms.
Alheraki SZ; Almquist DR; Starr JS; Halfdanarson TR; Sonbol MB
Clin Adv Hematol Oncol; 2023 Jan; 21(1):16-26. PubMed ID: 36638352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
